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Abstract: The prebiotic activity of a commercially available oat product and a novel oat ingredient,
at similar β-glucan loads, was tested using a validated in vitro gut model (M-SHIME®). The novel
oat ingredient was tested further at lower β-glucan loads in vitro, while the commercially available
oat product was assessed in a randomised, single-blind, placebo-controlled, and cross-over human
study. Both approaches focused on healthy individuals with mild hypercholesterolemia. In vitro
analysis revealed that both oat products strongly stimulated Lactobacillaceae and Bifidobacteriaceae
in the intestinal lumen and the simulated mucus layer, and corresponded with enhanced levels of
acetate and lactate with cross-feeding interactions leading to an associated increase in propionate
and butyrate production. The in vitro prebiotic activity of the novel oat ingredient remained at lower
β-glucan levels, indicating the prebiotic potential of the novel oat product. Finally, the stimulation of
Lactobacillus spp. was confirmed during the in vivo trial, where lactobacilli abundance significantly
increased in the overall population at the end of the intervention period with the commercially
available oat product relative to the control product, indicating the power of in vitro gut models in
predicting in vivo response of the microbial community to dietary modulation.
Keywords: Bifidobacterium; Lactobacillus; beta-glucan; intestine; microbiota; in vitro–in vivo correlation
1. Introduction
Prebiotics are defined as non-digestible substrates that are selectively utilised by the
gut microbiome, thereby conferring beneficial effects for the host [1]. Oat products contain
several soluble components capable of exerting prebiotic properties, such as β-glucans,
arabinoxylans, arabinogalactans, resistant starch, and polyphenolic compounds. However,
many of the health-promoting effects related to the consumption of oat products have
been attributed to the intake of β-glucans. These non-starch polysaccharides consist of
β-linked chains of D-glucose monomers, differing in their branching structure, viscosity,
solubility, and molecular weight [2], and they have been associated with a reduction of
systemic cholesterol levels [3], regulation of blood glucose concentrations, improved weight
management [4], and modulation of immune function [2].
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In order to exert their health-related properties, β-glucans need to be released from
the cell wall of the oat groats, a process which is highly affected by the applied process-
ing techniques. Indeed, hydrothermal processing has been linked with reduced release
of oat β-glucans [5]. Mechanical processing, on the other hand, results in increased ex-
tractability of β-glucans from the oat groats, probably by increasing the exposed surface
area [6]. Recently, Van den Abbeele et al. [7] reported an association between the β-glucan
content and the prebiotic potential of different oat ingredients that were produced by dif-
ferent mechanical processing techniques, suggesting that different processing techniques
might impact the potential functional properties of the final oat ingredients by affecting
β-glucan extractability.
Several human studies have explored the prebiotic activity of oat products [8–11].
Connolly et al. [11], for instance, investigated the prebiotic activity of whole-grain oat
granola, containing 1.3g β -glucan per dose in a human population with mild to moderate
hypercholesterolemia. It was shown that intake of whole-grain oat granola selectively
enhanced the abundance of Bifidobacterium and Lactobacillus species and total bacterial pop-
ulation compared to baseline levels, accompanied by reduced systemic levels of total and
LDL cholesterol. Indeed, numerous studies have linked the consumption of oat products
with hypocholesterolaemic effects [12–14]. While their cholesterol-lowering activity has
been associated with increased excretion of bile acids and cholesterol in faeces due to the
enhancement of viscosity of the intestinal content [15], recent research suggests a potential
role of the gut microbial community [16]. Indeed, modulation of the intestinal microbiota
might impact bile acid metabolism by stimulating bacterial bile salt hydrolase activity
of certain bacterial groups, thereby affecting cholesterol excretion [17,18]. Furthermore,
microbial production of propionate has been associated with a reduction of cholesterol
levels [19,20]. As several in vitro and in vivo studies have reported modulation of the gut
microbiota upon oat supplementation [11,21,22], a potential mechanism of action of oat
products in controlling cholesterol homeostasis might be related to its prebiotic properties.
Assessments of the prebiotic properties of dietary fibres are often performed during
in vitro studies. In vitro approaches offer an appropriate alternative to clinical trials because
interactions between the gut microbial community and dietary fibres can be investigated at
the site of action by strict control of environmental parameters [23,24].
As the prebiotic properties of oat ingredients might be involved in the lowering of
cholesterol levels, the initial aim of this study was to compare the prebiotic activity of a
commercially available oat product and a novel oat ingredient, standardised to provide
similar levels of β-glucan, in a model of the human gastrointestinal tract of different healthy
individuals with elevated cholesterol levels, making use of the validated Mucosal Simulator
of the Human Intestinal Microbial Ecosystem (M-SHIME®, ProDigest and Ghent University,
Ghent, Belgium) [25], in order to analyse potential similarity in prebiotic response of the
microbial community following oat consumption. Moreover, it was assessed if the potential
prebiotic properties of the novel oat product remained at lower β-glucan levels in terms
of effects on microbial metabolic activity and community composition of the luminal and
mucosal gut microbiome in vitro. Finally, a clinical trial, with a corresponding human
population, was carried out with the commercially available oat product in order to
determine if in vitro observations translated in vivo to provide evidence that the use of
in vitro gut models can be used to predict dietary outcomes following supplementation of
novel ingredients in vivo.
2. Results
2.1. Altered Microbial Metabolic Activity in Response to Oat Treatment in vitro
The short-chain fatty acids (SCFAs) detected consisted mainly of acetate, propionate,
and butyrate (Figure 1) and trace amounts of branched-chain fatty acid (bCFA) (Figure 1).
First, all test conditions significantly increased acetate (p < 0.0001), propionate (p < 0.0001),
and butyrate (p < 0.0001) levels in both colon regions as compared to the control period. The
only exception was noted in the proximal (PC) upon supplementation of pre-cooked oat
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flour (POF) at a concentration of 1.4 g β-glucan/day, where a marked, but not statistically
significant (p = 0.211), increase in butyrate levels was still observed (+13.2 mM). The latter
could be due to the fact that lactate most strongly accumulated (Figure 1) for this condition
(i.e., an average increase in lactate levels of 11.3 mM). While acetate and propionate levels
were not significantly different as a consequence of the supplementation of old-fashioned
oats (OFO) relative to POF at a concentration of 1.4 g β-glucan/day in the PC, butyrate
levels were significantly higher upon treatment with OFO in the PC (p < 0.0001), with an
additional average increase of 8.3 mM upon OFO fermentation as compared to POF. In the
DC, no significant differences in acetate and butyrate production were observed between
supplementation of OFO and POF at a concentration of 1.4g β-glucan/day, whereas POF
more strongly enhanced propionate production as compared to OFO (i.e., on average
an additional increase of 10.2 mM) in this colonic region (p = 0.007). With respect to
the different doses of POF, acetate, propionate, and butyrate levels increased in a dose-
dependent manner in the distal colon (DC), with the highest final SCFA levels observed
upon supplementation of the highest concentration of POF.
In terms of lactate production (Figure 1), a significant increase in lactate levels was
observed in the PC in response to the different treatments, whereas lactate levels remained
around the detection limit in the DC. In both colon regions, lactate levels were not signif-
icantly different between OFO and POF dosed at a concentration of 1.4 g β-glucan/day.
Furthermore, lactate levels increased in a dose-dependent manner in the PC for the differ-
ent doses of POF, with the highest lactate levels being observed upon supplementing the
highest dose of POF.
With respect to markers of proteolytic fermentation (Figure 1), all treatments signifi-
cantly increased ammonium and bCFA levels in response to the treatment in both colon
regions, except for bCFA levels in the PC upon supplementation of POF at a concentration
of 1.4 g β-glucan/day (p = 0.279). Overall, significantly lower ammonium and bCFA levels
were observed in the PC for POF versus OFO at a concentration of 1.4 g β-glucan/day
(p < 0.0001). Furthermore, in the PC, supplementation of POF at the highest concentration
tested resulted in the lowest production of bCFA and ammonium, indicating the presence
of a dose-response effect. In the DC, an opposite trend was observed.
2.2. Altered Microbial Composition in Response to Oat Treatment in vitro
To compare the prebiotic properties of the different test products and conditions, qPCR
analysis of specific health-related groups (Bifidobacterium spp. and Lactobacillus spp.) was
performed (Table 1). First, luminal Lactobacillus levels increased significantly in both colon
regions upon treatment with the different test products. Overall, the strongest increase was
observed upon supplementation of POF at a concentration of 1.4 g β-glucan/day, resulting
in significantly higher Lactobacillus levels as compared to the other test conditions (only
POF at a concentration of 1.0 g β-glucan/day resulted in similar increases in the luminal
DC). Similar effects were observed for Bifidobacterium levels, which significantly increased
in the luminal environment of both colon regions upon treatment with all the different test
products. It was noted that OFO more strongly stimulated Bifidobacterium levels than POF
at a concentration of 1.4 g β-glucan/day in the PC. Overall, effects on mucosal microbes
(Table 1) were similar to the changes reported for the luminal microbiota, even though less
pronounced, showing that the test products were able to stimulate the luminal and the
mucosal levels of bifidobacteria and lactobacilli.
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Figure 1. Effects on primary microbial metabolites. The average increase in (A) acetate (mM), (B) lactate (mM), (C) propi-
onate (mM), (D) butyrate (mM), and (E) branched-chain fatty acid (bCFA; mM) and (F)ammonium (mg/L) levels during 
the treatment period as compared to the control period upon treatment with old-fashioned oats (OFO) at a dose of 1.4 g/d 
and pre-cooked oat flour (POF) at a dose of 0.6 g/d, 1.0 g/d, and 1.4 g/d in the proximal (PC) and distal colon (DC) of the 
human gastrointestinal tract for three human donors tested. For optimal observation of consistent effects over the different 
Figure 1. Effects on primary microbial metabolites. The average increase in (A) acetate (mM), (B) lactate (mM), (C) propi-
onate (mM), (D) butyrate (mM), and (E) branched-chain fatty acid (bCFA; mM) and (F) ammonium (mg/L) levels during
the treatment period as compared to the control period upon treatment with old-fashioned oats (OFO) at a dose of 1.4 g/d
and pre-cooked oat flour (POF) at a dose of 0.6 g/d, 1.0 g/d, a d 1.4 g/d in the proximal (PC) and distal c lon (DC) of the
human gastrointestinal tract for three human donors tested. For optimal observation of consistent effects over the different
donors tested, the average of the three donors is presented (n = 3). Statistically significant differences relative to the control
period are indicated with *, whereas statistically significant differences between the different test conditions, in the proximal
and distal colon, respectively, are indicated with different letters (p < 0.05).
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Table 1. Effects on microbial community composition as assessed through qPCR. The average increase in Lactobacillus and Bifidobacterium levels (16S rRNA gene copies/mL for lumen and
16S rRNA gene copies/g for mucus) during the treatment period as compared to the control period upon treatment with OFO at a dose of 1.4 g/d and POF at a dose of 0.6 g/d, 1.0 g/d,
and 1.4 g/d in the luminal and mucosal environment of the proximal (PC) and distal colon (DC) of the human gastrointestinal tract for three human donors tested. For optimal observation
of consistent effects over the different donors tested, the average of the three donors is presented (n = 3). The intensity of the shading correlates with the absolute abundance, which is
normalised for each of the different bacterial groups in the different colonic environments, respectively. Statistically significant differences relative to the control period are indicated with
underlining (p < 0.05). Statistically significant differences between the different test conditions within a colonic region are indicated with different letters (a, b, c), with conditions not



















Lumen 3.5 × 108 a 1.4 × 109 a 6.2 × 109 b 4.3 × 108 a 1.5 × 108 a 9.1 × 108 b,c 5.6 × 109 b 2.8 × 108 a,c
Mucus 2.4 × 109 a 4.0 × 109 a,b 3.3 × 109 b 1.2 × 109 a,b 6.0 × 107 a 7.8 × 107 a,b 1.3 × 109 b 8.7 × 107 a
Bifidobacterium Lumen 4.5 × 10
9 a,b 9.0 × 109 a 4.5 × 109 b 7.2 × 109 a 1.4 × 109 a 4.2 × 109 b 4.3 × 109 b 3.6 × 109 b
Mucus 5.3 × 109 a,b 1.4 × 1010 a 9.2 × 109 b 1.0 × 1010 a 2.3 × 108 5.8 × 108 1.1 × 109 5.6 × 108
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In order to investigate more extensively the effects of treatment with OFO and POF
at a dose of 1.4 g β-glucan per day on microbial community composition, microbiome
profiling of the luminal PC and DC compartment was performed using 16S-targeted
Illumina sequencing. At phylum level (Figure 2), it was noted that at the main site of
fermentation, i.e., the lumen of the PC, both test products strongly increased Actinobacteria
levels. Similar observations were made in the DC. Additionally, a consistent increase
in Firmicutes levels was observed upon treatment with POF in the PC and DC, while
supplementation of OFO resulted in enhanced Proteobacteria levels.
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Figure 2. Microbial community composition as assessed via 16S-targeted Illumina sequencing. Abundance (%) at microbial
phylum level in the luminal environment of the proximal (PC) and distal colon (DC) of the human gastrointestinal tract at
the end of the control (C; n = 6/donor) and the treatment (TR; n = 3/donor) period upon treatment with OFO at a dose of
1.4 g/d and POF at a dose of 1.4 g/d for three human donors tested. For optimal observation of consistent effects over the
differ n donors tested, the average of the three donors is presented (n = 3).
At the family le el, t e ri r f c s as on the treatment effects of POF and OFO,
at a concentrati f . -glucan/day, at the main site of fermentation, i.e., the lumen
of the PC (Table 2). For the luminal DC (Table 3), simila observations were mad and
the f re only specific and distinct changes versus th PC referred to here. First, treatment
with POF and OFO strongly increase Bifidobact riac ae levels (p < 0.0001). At the oper-
a ional taxonomic unit (OTU) level, this was m inly a tributed to a s gnificant increase
in Bifidobacteriaceae OTU 1 (r la ed to Bifidobacterium adolescentis). To a lesser extent, Bi-
fidob teriaceae OTU 41 (related to Bifidobacteri bifi um) and Bifidobacteriaceae OTU 47
(related to Bifidobacteri longum) were stimulated. A sig ific nt crease in the abund nce
of L tobacillace e was observed upon tr a ment wi both test produc s, with the strongest
e fects for P F supplementation. The increased abundance of Lactobacillac ae was mainly
attributed to i creased abundance of Lactobacill ceae OTU 5 (related to Pedioco cus
acidilactici). Furthermore, upon treatment with both test products, Enterococcaceae, Enter-
obacteri ceae (p < .0001), and Prevotellaceae were significantly enric d in the luminal PC,
while Akkermansiaceae (p = 0.0031 for POF and p = 0.0118 for OFO) and Enterobacteriaceae
(p < 0.0001) were enhanced in the luminal DC. For the latter bacterial family, treatment
with OFO resulted in a stronger enrichment as compared to POF supplementation in both
Pathogens 2021, 10, 235 7 of 18
the PC (p < 0.0001) and DC (p < 0.0001). For POF, an increased abundance of Veillonel-
laceae was observed upon treatment (p < 0.0001 in PC and p = 0.0007 in DC), which was
mainly attributed to an increase in Veillonellaceae OTU 22 (related to Veillonella parvula)
and Veillonellaceae OTU 11 (related to Veillonella ratti). Furthermore, treatment with POF
consistently decreased Bacteroidaceae (p < 0.0001) and Lachnospiraceae (p < 0.0001) levels in
the luminal PC, resulting in significantly (p < 0.0001) lower levels as compared to treatment
with OFO. Treatment with OFO, on the other hand, resulted in increased Acidaminococcaceae
levels in the PC, while in the DC, Bacteroidaceae levels decreased (p = 0.0063) at the expense
of Prevotellaceae (p = 0.0019). Finally, the butyrate-producing Ruminococcaceae family was
stimulated significantly in the PC environment upon treatment with the different test
products, while decreased abundance was observed in the DC (p = 0.0009 for POF and
p < 0.0001 for OFO).
Table 2. Effects on microbial community composition at the family level in the proximal colon. Abundance (log counts/mL)
of microbial families in the luminal environment of the proximal colon (PC) of the human gastrointestinal tract at the end of
the control (C; n = 3/donor) and the treatment (TR; n = 3/donor) period upon treatment with OFO at a dose of 1.4 g/d and
POF at a dose of 1.4 g/d for three human donors tested. For optimal observation of consistent effects over the different
donors tested, the average of the three donors is presented (n = 3). The intensity of the shading correlates with the absolute
abundance, which was normalised for each of the different families. Statistically significant differences relative to the control
period are indicated in bold (p < 0.05). Statistically significant differences between the different test products (i.e., TR–POF
versus TR–OFO) are indicated with different letters (a, b), with conditions not sharing a similar letter being significantly
different from each other (p < 0.05).
Proximal Colon
POF OFO
C TR C TR
Actinobacteria
Bifidobacteriaceae 6.83 8.03 6.94 8.12
Coriobacteriaceae <LOD 5.76 <LOD 5.10
Bacteroidetes
Bacteroidaceae 7.53 6.01 7.55 7.85
Muribaculaceae <LOD <LOD <LOD 4.37
Prevotellaceae 5.04 7.65 4.73 7.12
Rikenellaceae 4.32 4.20 4.34 5.41
Tannerellaceae 5.64 4.67 5.92 6.58
Firmicutes
Acidaminococcaceae 6.53 5.36 5.20 7.25
Enterococcaceae 3.36 5.34 3.53 7.53
Erysipelotrichaceae <LOD 4.11 4.64 4.72
Lachnospiraceae 7.33 5.86 7.37 7.76
Lactobacillaceae 3.45 7.78 3.51 6.32
Ruminococcaceae 3.60 4.09 3.71 4.80
Veillonellaceae 6.96 7.93 7.14 7.20
Fusobacteria Fusobacteriaceae <LOD <LOD 4.21 4.89
Proteobacteria
Burkholderiaceae 5.15 5.62 5.62 6.65
Desulfovibrionaceae 5.40 4.41 5.66 4.93
Enterobacteriaceae 4.91 5.99 5.27 7.50
Pseudomonadaceae 4.75 4.14 5.20 4.59
uncultured <LOD <LOD 3.24 4.20
Synergistetes Synergistaceae 4.59 3.88 3.81 4.70
Verrucomicrobia Akkermansiaceae <LOD <LOD 3.61 3.94
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Table 3. Effects on microbial community composition at the family level in the distal colon. Abundance (log counts/mL) of
microbial families in the luminal environment of the distal colon (DC) of the human gastrointestinal tract at the end of the
control (C; n = 3/donor) and the treatment (TR; n = 3/donor) period upon treatment with OFO at a dose of 1.4 g/d and
POF at a dose of 1.4 g/d for three human donors tested. For optimal observation of consistent effects over the different
donors tested, the average of the three donors is presented (n = 3). The intensity of the shading correlates with the absolute
abundance, which was normalised for each of the different families. Statistically significant differences relative to the control
period are indicated in bold (p < 0.05). Statistically significant differences between the different test products (i.e., TR–POF
versus TR–OFO) are indicated with different letters (a, b), with conditions not sharing a similar letter being significantly
different from each other (p < 0.05).
Distal Colon
POF OFO
C TR C TR
Actinobacteria
Bifidobacteriaceae 7.39 8.26 7.45 8.13
Coriobacteriaceae 5.61 5.31 5.66 4.93
Bacteroidetes
Bacteroidaceae 8.35 8.20 8.30 8.04
Muribaculaceae 5.26 6.23 4.87 6.02
Prevotellaceae 6.55 6.95 6.27 7.22
Rikenellaceae 6.29 5.74 6.12 6.10
Tannerellaceae 7.26 7.84 7.28 7.64
Firmicutes
Acidaminococcaceae 6.61 7.22 6.79 6.94
Enterococcaceae 4.39 6.11 4.34 7.88
Erysipelotrichaceae 5.64 4.86 5.65 <LOD
Lachnospiraceae 8.23 8.28 8.16 8.27
Lactobacillaceae 4.53 8.25 4.45 6.76
Ruminococcaceae 6.64 6.12 6.74 5.90
Veillonellaceae 7.37 8.04 7.34 7.36
Fusobacteria Fusobacteriaceae 5.62 6.34 5.70 7.66
Proteobacteria
Burkholderiaceae 6.48 6.73 6.52 6.31
Desulfovibrionaceae 6.58 6.79 6.76 6.94
Enterobacteriaceae 5.42 6.36 5.45 7.63
Pseudomonadaceae 6.57 5.52 6.44 6.48
uncultured 5.89 6.51 6.05 6.33
Synergistetes Synergistaceae 6.93 7.52 7.16 7.27
Verrucomicrobia Akkermansiaceae 7.24 7.67 7.41 7.77
2.3. In vitro–in vivo Comparison of Microbial Response to OFO Treatment
In vitro, the prebiotic activity of OFO was characterised by a significant stimulation
of lactobacilli and bifidobacteria in both the luminal and mucosal environment (Table 1).
Therefore, selective primers were selected to analyse the levels of Lactobacillus spp. and
Bifidobacterium spp. in the faecal samples collected during the in vivo trial by means of
quantitative polymerase chain reaction (qPCR). During the in vivo trial, stimulation of
Lactobacillus spp. was observed (Figure 3A). Indeed, significant stimulation of Lactobacillus
species was observed at the end of the intervention period with OFO as compared to the
control test product for the overall population (p = 0.037) and in the population designated
as ‘Group 2’, i.e., the group that received the investigational product during the second
intervention period (p = 0.017; Figure 3A). For Bifidobacterium levels (Figure 3B), no overall
significant differences were observed between intervention with OFO and the control
test product, although a trend towards increased Bifidobacterium levels was observed
upon intervention with OFO in the ‘Group 1’ population (i.e., the group that received
the investigational product during the first intervention period) (p = 0.299). With respect
to plasma SCFA levels, no statistically significant differences were observed between
intervention with OFO and the control test product.
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Figure 3. Effects on microbial community composition in vivo. Effect of intervention with OFO (TR)
on faecal (A) Lactobacillus and (B) Bifidobacterium levels as compared to an intervention with the
control test product (C) during a randomised, single-blind, cross-over study in healthy individuals
with elevated cholesterol levels for the per protocol (PP) population, with samples taken at baseline
(week_00), at the end of the intervention period (week_06) and at the end of the washout period
(week_10). Results are presented for Group 1 (received OFO during the first intervention period),
Group 2 (received OFO duri g the second intervention period), and the overall (Group 1 + 2)
population. Results are presented as mean (16S rRNA gene copies/ng DNA). * indicates statistically
significant differences between control and treatment within a specific experimental week for Group 1,
Group 2, and Group 1 + 2 (p < 0.05).
3. Discussion
In the present study, the potential prebiotic effects of prolonged administration of
the commercially available oat product OFO were assessed in the human gastrointestinal
tract of different healthy individuals with mild hypercholesterolemia. For this purpose, the
validated in vitro M-SHIME® model [25] was utilised, allowing analysis of an intestinal mi-
crobial community that is fully stable prior to treatment [26]. It followed that the prebiotic
activity of OFO was characterised by strong stimulation of Lactobacillus and Bifidobacterium
species in the intestinal lumen and the simulated mucus layer of the PC and DC. Lacto-
bacilli [27] and bifidobacteria [28] are saccharolytic gut microbes and are both capable of
producing high levels of lactic acid, thereby exerting antimicrobial properties [29] and
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stimulating trophic interactions with other bacteria resulting in the production of secondary
metabolites such as butyric acid [30]. Due to their saccharolytic metabolism, Lactobacil-
lus and Bifidobacterium species mainly thrive in the proximal regions of the colon [31].
Therefore, the effects of prebiotic compounds on these bacterial groups are often more
difficult to observe in in vivo trials. However, during the current study, the stimulation
of Lactobacillus spp. by OFO was also observed in the faecal samples of human subjects
with mild hypercholesterolemia during the randomised, single-blind, placebo-controlled,
cross-over study. This is a striking observation as in vivo studies are inherently confounded
by large variability due to interindividual differences among individuals and a strong
influence of external factors such as diet [32]. Moreover, the investigated in vivo samples
considered faecal samples that are only to a limited extent representative for the microbial
changes in the PC. For Bifidobacterium levels, no significant differences were observed be-
tween intervention with OFO and the control test product, although in the population that
received OFO during the first intervention period a trend towards increased Bifidobacterium
levels was observed upon intervention with OFO. Overall, existing scientific evidence
and the preliminary results in this study show the significant stimulatory effects of OFO
on lactobacilli in human subjects with mild hypercholesterolemia, which points to the
prebiotic potential of OFO. Because it has been reported extensively that lactobacilli and
bifidobacteria exert hypocholesterolaemic effects both in both animals and humans [33–36],
further in vivo studies are warranted to explore this effect for OFO. Furthermore, as stimu-
lation of Lactobacillus spp. by OFO in vivo correlated with the obtained in vitro data, the
current study shows that in vitro gut models might be an interesting tool in predicting
in vivo response of the microbial community to dietary modulation.
The in vitro component of the current study also aimed to assess the prebiotic potential
of a novel oat product, i.e., POF, relative to OFO. It was revealed that both exerted a highly
similar prebiotic activity. First, both test products resulted in significantly higher levels of
acetate and lactate, which correlated with the strongly enhanced levels of Lactobacillaceae
and Bifidobacteriacea species [31], indicating the involvement of these bacterial groups
in primary substrate degradation upon supplementation of the different oat products.
At the OTU level, the main changes were attributed to a significant increase in an OTU
related to Bifidobacterium adolescentis. It has been previously reported that fermentation
of oat bran stimulates the growth of Bifidobacterium adolescentis in vitro [37], while also
fermentation of β-glucans has been associated with this bacterial species [38]. The signif-
icant stimulation of Lactobacillaceae upon treatment with the different test products was
linked with increased abundance of an OTU related to Pediococcus acidilactici, which has
been associated with immune-enhancing effects [39]. Furthermore, both test products
enhanced Akkermansiaceae levels in the DC. The only representative of Akkermansiaceae in
the gut is the mucin-degrading Akkermansia muciniphila, which has been correlated with
several health benefits, such as the inverse relationship between colonisation of Akkerman-
sia muciniphila and inflammatory conditions [40]. Additionally, significantly enhanced
levels of propionate and butyrate were observed upon administration of both test ingre-
dients. Administration of oat products has previously been linked with increased levels
of butyrate [41,42]. Indeed, Knudsen et al. [42] reported that addition of oat bran to the
diet of pigs increased butyrate concentrations in the luminal environment of the porcine
colon. However, administration of β-glucan enriched oat fractions to the porcine diet did
not result in butyrate enrichment, indicating that other dietary components (e.g., arabi-
noxylans) are responsible for the observed increase in butyrate concentration upon oat
supplementation. β-glucans on the other hand have been shown to selectively stimulate
propionate levels in the colonic environment [7,43,44]. It was proposed that the hypoc-
holesterolaemic effect of oat fibres [12–14] might be associated with this propionogenic
response. Indeed, upon its production, propionate is transported to the liver, where it
impacts cholesterol and fatty acid synthesis [19,20]. Moreover, next to the reduction of
cholesterol levels, health-beneficial effects of propionate include weight management by
stimulation of satiety [45], regulation of immune function in adipose tissue [46,47], and
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protection against cancer development [48]. The stimulation of SCFA production by the
different oat ingredients therefore suggests their prebiotic potential.
In addition, some differences were observed between the fermentation of OFO and
POF. For instance, supplementation of POF resulted in the strongest stimulation of Lac-
tobacillus levels in the PC and DC, while OFO administration more strongly enhanced
butyrate production and Bifidobacterium concentrations in the PC. Previous in vitro research
by Van den Abbeele et al. [7] revealed that product-specific microbial pathways were
boosted upon administration of structurally different oat ingredients. For instance, while
all products resulted in a significant increase in Bifidobacterium levels, oat bran showed the
strongest bifidogenic effect of the six oat ingredients investigated, indicating that slight
differences in prebiotic response exist among oat-derived products, as observed in the
current study.
Moreover, in vitro investigations were carried out to determine if the potential prebi-
otic properties of the novel oat product POF persisted at lower test doses. It was observed
that acetate, propionate, and butyrate levels increased in a dose-dependent manner in
the DC with the highest final SCFA levels observed upon supplementation of the highest
concentration of POF. However, even at the lowest concentration tested, POF stimulated
SCFA production and Lactobacillus and Bifidobacterium levels, indicating that the prebiotic
activity of POF remained at lower β-glucan levels. Overall, the obtained results demon-
strate the prebiotic potential of the novel oat product POF, even when administered at
lower concentrations.
In order to further investigate the impact on the luminal microbial community com-
position upon supplementation of POF and OFO at similar β-glucan load, 16S-targeted
Illumina sequencing was performed. Treatment with both test products increased Prevotel-
laceae levels, mainly in the PC. Saccharolytic fermentation by members of this bacterial
family results in the production of acetate and succinate [49], with the latter being a sub-
strate for succinate-converting, propionate producing micro-organisms such as Bacteroides
and Veillonella species [50]. In the current study, an increased abundance of Veillonellaceae
was observed upon treatment with POF, but not upon OFO supplementation. However,
it might be that specific members of the Veillonellaceae family were stimulated upon OFO
administration, while others reduced, resulting in the absence of effects at the family level.
Finally, both test products increased the abundance of Enterobacteriaceae. This bacterial
family contains several opportunistic pathogenic species, however, also many commensals
able to ferment proteins are members of this bacterial group [51]. The strongest effects were
observed upon OFO supplementation, which correlated with the more strongly increased
levels of branched SCFA and ammonium, which are both markers of proteolysis that were
observed upon fermentation of OFO as compared to POF. Overall, these results indicate
that in vitro gut models combined with accurate molecular techniques have the potential
to highlight specific microbial taxonomic changes and functional activities pathways upon
dietary intervention.
From this study, it can be concluded that the novel oat product POF and the com-
mercially available OFO, when administered at similar β-glucan load, exerted equivalent
prebiotic activity in the human gastrointestinal tract in vitro, with profound effects being
observed on Lactobacillus and Bifidobacterium levels. The stimulation of Lactobacillus spp.
observed in vitro was confirmed during an in vivo trial investigating the effect of OFO in
human subjects with mild hypercholesterolemia. Moreover, the in vitro prebiotic activity
of POF remained at lower β-glucan levels, demonstrating the potent prebiotic potential of
the novel oat product even when administered at lower concentrations.
4. Materials and Methods
4.1. Chemicals and Test Product
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich (Overijse,
Belgium). PepsiCo, Inc. (Barrington, IL, USA) provided the different oat ingredients,
including Quaker whole grain pre-cooked oat flour (POF) and old-fashioned oats (OFOs).
Pathogens 2021, 10, 235 12 of 18
OFOs were produced by steaming the whole groats to make them soft and pliable and then
pressed to flatten them obtaining a particle size of 0.51−0.76 mm. POF was produced using
PepsiCo’s proprietary process providing a ready-to-use format with improved dispersibility.
The granulation range for POF ranged from 50–250 µm with the targeting of 178–250 µm.
The daily dose of both oat ingredients during the in vitro experiment was standardised to
provide 1.4g β-glucan once per day. For POF, two additional test doses were investigated—
standardised to provide 0.3 g β-glucan twice per day (to total 0.6 g β-glucan per day) and
1.0 g β-glucan once per day. In order to mimic the in vivo conditions as close as possible,
the test ingredient OFO was cooked according to the manufacturer’s instructions prior
to use in the in vitro experiment. During the in vivo study, dry OFO was supplied to the
subjects and cooked according to the manufacturer’s instructions prior to consumption.
The consumption of cooked OFO was investigated during an intervention period of six
weeks, providing a daily one serving dose of 40 g oats containing 1.4 g β-glucan. The
control test product during the in vivo trial was Cream of Rice (Nabisco, East Hanover, NJ,
USA), a cooked cereal containing no fibre or β-glucan and was supplemented at a dose of
40 g per day.
4.2. Simulator of the Human Intestinal Microbial Ecosystem (SHIME®)
The reactor setup simulating the human gastrointestinal tract was derived from the
SHIME® (ProDigest and Ghent University, Ghent, Belgium) as described by Molly et al. [23].
To optimally address the research questions, the SHIME® setup was adapted from a single
SHIME configuration (including one SHIME® arm) to a TripleSHIME® configuration (in-
cluding three SHIME® arms). Each arm of the TripleSHIME® consisted of a succession of
three reactors simulating the different regions of the gastrointestinal tract. The first reactor
mimicked the upper gastrointestinal tract with the subsequent simulation of a gastric
and small intestinal phase. The two subsequent colonic reactors simulated the proximal
colon (PC), operated at pH 5.6–5.9 with a retention time of 20 h, and the distal colon
(DC), operated at pH 6.6–6.9 with a retention time of 32 h. In order to simulate both the
luminal and mucus-associated microbial community in the colonic reactors, mucin-covered
beads were included as described by Van den Abbeele et al. [25]. Inoculum preparation,
temperature settings, feeding regime, and reactor feed composition were adopted from
Possemiers et al. [52]. To evaluate the properties of four different test ingredients and/or
concentrations, four parallel TripleSHIME® experiments were executed using the micro-
biota of three healthy adult human donors with elevated total and low-density lipoproteins
(LDL) cholesterol levels (total ≥ 5.5 mmol/L and <7 mmol/L and LDL ≥ 3.4 mmol/L
and ≤ 4.9 mmol/L) and a BMI between 20 kg/m2 and 25 kg/m2 (donor A: F, 25 y; donor
B: F, 30 y; Donor C: M, 35 y), meaning that each test ingredient/concentration was tested
in a separate TripleSHIME® experiment including the microbial community of three dif-
ferent donors. Upon inoculation with the faecal inoculum from the different donors, a
two-week stabilisation period was initiated allowing the faecal microbiota to differentiate
in the colonic reactors depending on the local environmental conditions. Subsequently,
the baseline microbial community composition and activity were determined in the PC
and DC during a two-week control period, followed by an evaluation of the effects of
repeated daily administration of the test products during a three-week treatment period.
The test products were pre-digested prior to administration to the colonic reactors in order
to produce relevant product fractions that would reach the colonic environment. Pre-
digestion was performed as previously described by Van den Abbeele et al. [7], with some
minor modifications. During the oral phase, the test ingredients were diluted to obtain a
concentration mimicking the daily test doses of interest, corrected for moisture content.
Furthermore, the intestinal dialysis approach included a 4.5-hour incubation, during which
the dialysis fluid was replaced once every 45 minutes with fresh fluid.
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4.3. In vivo Study
This was a randomised, single-blind, placebo-controlled, and cross-over study to
assess the effect of hot cooked OFO on a range of variables including faecal bacterial
composition and plasma SCFAs, in a sample of healthy adults with elevated cholesterol
levels within the same range as the in vitro study. There were six visits in total with two
phases to data collection (Figure S1). Each phase consisted of a 10-week period. The trial
phase comprised of a six-week intervention period (Week 0–Week 6) after which subjects
completed a four-week washout (Week 10).
In total, 34 randomised subjects (aged 18–65 years old, BMI of 18.5–30 kg/m2, fasting
blood glucose (FBG) of 3.0–6.0 mmol/L) were included in the analysis. To enrol in the trial,
subjects provided written informed consent, and then completed the required screening
procedures to evaluate their eligibility for the trial. At screening (Visit 1), fasting blood
samples were collected to examine potential subject’s safety and blood lipid profiles, the
subjects were also administered a food frequency questionnaire (FFQ); this information
determined eligibility. The study participants were required to have a low to moderate
consumption of dietary fibre based on data from the 2008–2010 Irish National Adult Nutri-
tion Survey [53] (Low- fibre diet: ≥9.9 g/d and ≤17 g/d for males; 8.2 g/d and ≤14.3 g/d
for females; moderate extends to 25.1 g/d for males and to 22.3 g/d for females), and
elevated total and LDL cholesterol levels (total cholesterol ≥ 5.5 and <7 mmol/L and
LDL ≥ 3.4 mmol/L and ≤ 4.9 mmol/L). The trial included a two-week run-in period to
washout possible pre-trial prebiotics prior to baseline assessment. Eligible subjects were
then randomised in a 1:1 ratio at Visit 2 to receive either treatment or control product in
Phase 1 (Baseline: Visit 2; Week 0—End of Phase 1: Visit 3 at Week 6; Washout period:
Visit 4 at Week 10), and they would then cross-over to consume the alternative product for
Phase 2 (Baseline: Visit 4 at Week 10; Week 10—End of Phase 2: Visit 5 at Week 16; Washout
period: Visit 6 at Week 20). Group 1 received OFO during the first intervention period and
Cream of Rice during the second intervention period, while Group 2 received Cream of
Rice during the first intervention period and OFO during the second intervention period.
Subjects were provided with a stool collection kit at visits 1, 2, 3, 4, and 5 and instructed to
collect a sample at home (24 hours prior to their visit) and bring it to the clinic at their next
visit. Samples were kept chilled preceding analysis.
The subjects consumed the study product once daily, at breakfast, for six weeks
starting on Day 1, the day after Visit 2. The subjects were asked not to consume any other
prebiotic/probiotics and fibre supplements or whole-grain oat products throughout the
duration of the trial (22 weeks). They were also asked to maintain their habitual lifestyle in
relation to physical activity level and diet.
Ethical approval was granted by the Clinical Research Ethics Committee, Cork Ireland,
prior to the study starting with code ECM 5 (6) 17/01/18. The study was conducted
according to the principles of ICH-GCP and the Declaration of Helsinki.
4.4. Microbial Metabolic Activity
During the in vitro SHIME® experiment, samples for analysis of microbial metabolic
activity were collected three times per week during the control and treatment period from
each colonic reactor. Short-chain fatty acid (SCFA) measurements were performed as
described by De Weirdt et al. [54] and included acetate, propionate, butyrate, and branched-
chain fatty acids (isobutyrate, isovalerate, and isocaproate; bCFA). Lactate levels were
determined using a commercially available enzymatic assay kit (R-Biopharm, Darmstadt,
Germany) according to the manufacturer’s instructions. Ammonium determination was
conducted as previously reported by Duysburgh et al. [55].
During the in vivo experiment, samples for analysis of plasma SCFA were collected
at each scheduled visit, starting from Visit 2. Four plasma samples were collected in total
per participant, i.e., one sample per baseline and endpoint of Phase 1 and Phase 2 of the
in vivo experiment. Samples were prepared, extracted, and subjected to Ultra Performance
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Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS; Waters Ltd. Herts, United
Kingdom) and analysed according to Brown et al. [56].
4.5. DNA Extraction
During the control and treatment period of the in vitro SHIME® experiment, samples
for microbial community analysis were collected once per week from each colonic reactor.
Total DNA was isolated as described by Boon et al. [57], with some minor modifications as
previously reported by Duysburgh et al. [55]. For the in vivo study, metagenomic DNA was
extracted from all faecal samples by Teagasc (Cork, Ireland) using a modified version of the
QIAGEN FAST Stool extraction kit (QIAGEN, Manchester, UK). The modification included
an additional bead-beating step at the start of the procedure. Briefly, faeces were added to
the buffer as described by the manufacturer’s instructions, after which homogenisation
with a bead beater device was performed, followed by the protocol for Gram-positive
bacteria as described by manufacturer’s instructions.
4.6. Microbial Community Analysis through qPCR
qPCR assays to quantify Lactobacillus spp. and Bifidobacterium spp. were completed
using a QuantStudio 5 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA).
Each sample was analysed in technical triplicate and outliers (more than 1 CT difference)
were removed. The qPCR assay, including primer sequences and amplification program,
for Lactobacillus spp. was conducted as reported by Furet et al. [58], while the qPCR for
Bifidobacterium spp. was previously described by Rinttilä et al. [59].
4.7. Microbial Community Analysis through 16S-Targeted Illumina Sequencing
In order to compare effects on microbial community composition of treatment with
OFO and POF at a dose of 1.4 g β-glucan per day, microbial community profiling of the
luminal PC and DC compartment of the in vitro SHIME® experiment was performed using
16S-targeted Illumina sequencing. Library preparation and sequencing on an Illumina
MiSeq platform with v3 chemistry (2 × 300bp) were conducted by LGC Genomics GmbH
(Berlin, Germany) using the primers as reported by Klindworth et al. [60], with modifi-
cation of the reverse primer (785Rmod; 5’-GAC TAC HVG GGT ATC TAA KCC-3’) to
increase coverage.
4.8. Flow Cytometric Determination
Samples were also collected once per week from each colonic reactor for enumeration
of bacterial cells via flow cytometry. A 10-fold dilution series was prepared initially in
phosphate-buffered saline. Assessment of the viable, non-viable, and total population
of the microbial community was done by staining the appropriate dilutions with SYTO
24 and propidium iodide. Samples were analysed on a BD FACSVerse (BD Biosciences,
Erembodegem, Belgium). The samples were run using the high flow rate. Bacterial cells
were separated from medium debris and signal noise by applying a threshold level of
200 on the SYTO channel. Proper parent and daughter gates were set to determine all
populations. Results were obtained as log counts/mL.
4.9. Data and Statistical Analysis
For the analysis of 16S-targeted Illumina sequence data, read assembly and clean-up
was adopted from the MiSeq procedure [61,62]. Briefly, mothur (v. 1.40.5, University of
Michigan, Ann Arbor, MI, USA) was applied to assemble reads into contigs, perform
alignment-based quality filtering (alignment to the mothur-reconstructed SILVA SEED
alignment, v. 123), remove chimeras, assign taxonomy using a naïve Bayesian classifier [63]
and SILVA NR v132 and cluster contigs into operational taxonomic units (OTUs) at 97%
sequence similarity. All sequences classified as Archaea, Chloroplasts, Eukaryota, and
Mitochondria were omitted, in addition to sequences that could not be classified at all. For
each OTU, representative sequences were picked as the most abundant sequence within
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that OTU. To identify related bacterial species, the obtained sequences were matched using
the SeqMatch tool in the Ribosomal Database Project software (Michigan State University,
East Lansing, MI, USA) [64]. Results were presented as proportional values versus the
total amount of sequences within each sample. Combining the proportional values of
the 16S-targeted Illumina together with the enumeration of the total cell count obtained
through flow cytometry, as was previously described by Vandeputte et al. [65], provided
quantitative abundances of the different taxonomic entities inside the colonic reactors.
These quantitative abundances were obtained by multiplying the proportional values of
the 16S-targeted Illumina with the total log cell count obtained by flow cytometry.
With respect to microbial parameters during the in vitro SHIME® study, consistent
findings were made for the three different donors in response to the treatment with the
different oat products so that the averages of all parameters over the three donors were cal-
culated per colon compartment for optimal visualisation of donor-independent treatment
effects. Statistical analyses were carried out using Statistical Analysis Software version
9.4 (SAS Institute, Cary, NC, USA). Data were analysed by comparing the averages over
the three donors for the control period as compared to the treatment period, and for the
differences between the test product during the treatment period and this for both PC
and DC separately, using Bonferroni correction. For 16S-targeted Illumina sequence data,
statistical analysis was only performed for those bacterial families with complete data from
at least two donors to capture both the noise within each donor and variability between
donors. The significance level for all statistical tests was set at α = 0.05. Shapiro–Wilk
tests were conducted to assess the normality of the data. Log-transformation was applied
where appropriate.
For the in vivo study, outcomes were analysed on the per-protocol population (PP),
i.e., all subjects with complete data and at least 80% compliance in terms of the amount of
product consumed. Statistical analysis was performed using the SPSS Statistics software
(IBM, Armonk, NY, USA), version 25. Normality of data and equality of the variances
were determined with a Shapiro–Wilk test and a Levene’s test, respectively. For normally
distributed data with equal variances, a one-way ANOVA with a Bonferroni post hoc
test was used. For normally distributed data with unequal variances, a Welch test with a
Games–Howell post hoc test was conducted. For non-normally distributed data, a Kruskal–
Wallis one-way ANOVA test with multiple post hoc pairwise comparisons were performed.
In terms of statistics, the differences indicated by ‘p < 0.05’ were significant. All data were
normalised to the DNA concentration of the extracts obtained from the faecal samples.
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